By Sheeba M. | March 30, 2026
US MSOs vs. Canadian LPs: The Great Cannabis Portfolio Divergence of 2026
For most of the past five years, cannabis investors treated US MSOs and Canadian LPs as part of the same trade: “cannabis stocks.” They moved together. They rallied together. They crashed together. That era is over. In 2026, the two groups are telling radically different stories — and if you’re holding both in your portfolio without understanding why, you’re probably making a mistake.
The Rescheduling Reset
When the DEA finalized rescheduling to Schedule III in late 2025, the immediate beneficiary was the US cannabis industry. Section 280E relief alone represented an effective corporate tax rate reduction of 15-20 percentage points for many operators — a structural shift that showed up in Q1 2026 earnings beats across the sector. Green Thumb Industries (GTBIF), Curaleaf (CURLF), and Canopy Growth (CGC) all reported EBITDA improvements, but for very different reasons.
Canadian LPs — with the notable exception of those with meaningful US exposure — got almost nothing from rescheduling. Their products remain illegal at the federal level in the US. Their banks still won’t touch them for US-dollar denominated transactions. And their core markets, Canada and Germany, are dealing with their own regulatory headwinds and price compression.
The Capital Access Gap
This is where the divergence gets serious. US MSOs can now access institutional credit. Several mid-tier operators have already refinanced debt at rates that were unimaginable 18 months ago. Green Thumb closed a $150M credit facility with a major commercial bank in Q4 2025 — something that simply could not have happened before rescheduling.
Canadian LPs, by contrast, are still largely dependent on equity raises that dilute shareholders. Organigram (OGI) has done a respectable job managing its balance sheet, but the company is essentially running in place — generating revenue but lacking the capital infrastructure to scale production efficiently.
Where the Value Opportunity Lives
Here is the counter-intuitive part: Canadian LPs are cheaper on a pure multiples basis. Aurora Cannabis (ACB) and Hexo (HEXO) trade at fractions of their book value. If you believe the Canadian market will eventually consolidate and survivors will own the post-legalization landscape, the risk-reward on select LPs is asymmetric.
But “eventually” is doing a lot of work in that sentence. US MSOs are executing now. They have the infrastructure, the brands, and — post-rescheduling — the financial plumbing to build lasting businesses. Canopy Growth (CGC) is an interesting hybrid: a Canadian LP with aggressive US acquisition strategy that gives investors exposure to both stories through a single ticker.
For a pure US-focused portfolio, stick with operators that have proven cash flow, manageable debt, and state-level market leadership. Track them on the Weedstock Real-Time Tracker and build positions on dips — not headlines.